Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Pralidoxime chloride autoinjector is a small-molecule antidote administered intramuscularly for rapid treatment of organophosphate and carbamate poisoning. It reactivates acetylcholinesterase by removing phosphoryl groups from the enzyme active site, restoring normal neuromuscular function. This product represents a critical emergency medical countermeasure used in acute poisoning scenarios.
As LOE approaches with moderate competitive pressure (30%), commercial teams face declining market opportunity and potential headcount reductions or portfolio rebalancing.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on pralidoxime autoinjector offers narrow but specialized career opportunity in emergency preparedness and government/military channels rather than traditional pharma commercial roles. With LOE approaching and zero linked job openings, this product is best suited for professionals interested in niche public health applications or those seeking to stabilize a legacy product franchise.
Worked on PRALIDOXIME CHLORIDE (AUTOINJECTOR) at CooperSurgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.